Company News_News_Beijing Wista Pharma Co., Ltd_Beijing Wista Pharma Co., Ltd}

Pharmaceuticals / services

简体中文

Company News

082024-05

Our new formulation L-Ornithine-L-Aspartate Infusion for injection has been approved

Our new formulation L-Ornithine-L-Aspartate Infusion for injection( 5gm/10ml ) has been approved by China SFDA on 23th April 2020. The injection registration certificate No. is H20203173.
082024-05

Nafcillin Sodium for injection has been approved by China SF

Our new formulation Nafcillin Sodium for injection (1.0gram per ampoule) has been approved by China SFDA on 4th May 2015. The API registration certificate no. is H20153081 and its injection registrati
082024-05

Olopatadine hydrochloride tablets has been approved by China SF

Our new formulation Olopatadine hydrochloride tablets (5mg ) has been approved by China SFDA on 31st May 2022. The tablets registration certificate No. is H20213892 and H20223350.
082024-05

Voriconazole tablets has been approved by China SF

Our new formulation Voriconazole tablets (50mg and 200mg) has been approved by China SFDA on 24th Nov. 2021. The tablets registration certificate No. is H20213892 and H20213893.
082024-05

Luliconazole and posaconazole are launched into market

The synthesis pilots of Luliconazole and posaconazole are successfully completed.The key intermediates are available to international market from July 2013.

共5条
1

About News Product & Service

Innovation & Research Human Resource Contact Us

86-10-67887855

Head Office：5F, Building No.6, HAN's Enterprise Bay, Liangshuihe No.2 Street, Beijing Economic Technological Development Area, Beijing, 100176, P.R.China

Marketing：sales@51cns.com

R&D Department：RD@51cns.com

Wista Pharmam

j9·九游会游戏中国官方网站-真人游戏合营品牌

Company News

Our new formulation L-Ornithine-L-Aspartate Infusion for injection has been approved

Nafcillin Sodium for injection has been approved by China SF

Olopatadine hydrochloride tablets has been approved by China SF

Voriconazole tablets has been approved by China SF

Luliconazole and posaconazole are launched into market